News

New compound offers hope for deadly tropical disease

Schistosomiasis drug candidate overcomes limitations of current treatment
Nancy D. Lamontagne
March 24, 2024

A newly developed compound is showing promise in animal studies as a more effective treatment for human schistosomiasis, an understudied tropical disease caused by parasitic worms. The spread of schistosomiasis, a disease responsible for nearly 12,000 deaths globally each year, has been documented in 78 nations.

Although schistosomiasis transmission tends to occur in tropical and subtropical areas, climate change could shift it into new areas such as southern Europe. There is currently no vaccine available for the disease, which comes with severe clinical symptoms. The drug praziquantel is used for treatment. However, resistant mutations are reducing praziquantel’s efficacy, and the drug doesn’t kill the larval-stage parasites.

Researchers at Discover BMB in San Antonio report a new compound that shows promise as a more effective treatment for human schistosomiasis, an understudied tropical disease caused by parasitic worms. Here you can see the parasite’s eggs in a bladder.
Researchers at Discover BMB in San Antonio report a new compound that shows promise as a more effective treatment for human schistosomiasis, an understudied tropical disease caused by parasitic worms. Here you can see the parasite’s eggs in a bladder.

Sevan N. Alwan, an assistant professor at The University of Texas Health Science Center at San Antonio, led the research team.

 “The infection can become reactivated when the larva develop into adult parasites, which comes with more severe symptoms and higher transmission rates,” said Alwan, an assistant professor at The University of Texas Health Science Center at San Antonio. “The compound we developed overcomes the limitations of praziquantel by being effective against the larval stage and resistant strains.”

Alwan will present the research at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, which will be held March 23–26 in San Antonio.

“In recent reports, the cure rates for praziquantel were 60% in Sub-Saharan Africa, where the disease is highly endemic,” said Alwan. “The drug limitations strongly warrant the need for new therapeutics with a distinctly different mechanism of action to reach a better cure rate.”

The new compound was developed as part of the research team’s effort to design, synthesize and test reengineered derivatives of oxamniquine, which was previously used to treat patients with parasite but is no longer used due to drug resistance and limited effectiveness.

The researchers developed and tested 350 compounds. Five of these killed human Schistosoma species as well as a praziquantel-resistant strain in animal models.

One of these compounds, called CIDD-0149830, also killed larval parasites in experiments with cultured cells and a mouse model of the disease. In experimental groups of five female mice each, the number of larval worms was reduced by 71.7% with CIDD-0149830, while praziquantel reduced them by only 21.1%. The study also showed that CIDD-0149830 reduced the number of eggs more effectively.

“In addition to being effective against the larval stage and resistant strains, CIDD-0149830 also overcomes the limitation of oxamniquine by being effective against two major species of the parasite in animal models and can effectively treat mixed infection by these two species,” Alwan said.

Although the new results are promising, the researchers caution that they must still determine dosing for humans and perform safety and toxicity studies to make sure the treatment is safe for human use. They also plan to conduct experiments with male and female mice to assess whether sex influences the outcome of worm burden and morbidity.

Sevan N. Alwan will present this research during a poster session from 4:30 to 6:30 p.m. CDT on Sunday, March 24, in the exhibit hall of the Henry B. González Convention Center (Poster Board No. 56) (abstract). 

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Nancy D. Lamontagne

Nancy D. Lamontagne is a science writer and editor at Creative Science Writing based in Chapel Hill, North Carolina.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Gene-mutation pathway discovery paves way for targeted blood cancers therapies
News

Gene-mutation pathway discovery paves way for targeted blood cancers therapies

Nov. 3, 2024

A new study by researchers at the universities of Texas and Chicago explains the enzymatic activity that’s needed for tumor suppression in leukemias and other cancers.

Candy binges can overload your gut microbiome
News

Candy binges can overload your gut microbiome

Nov. 2, 2024

While most Halloween candies contain lots of sugar, some are better for your gut microbiome than others.

Water rescues the enzyme
Essay

Water rescues the enzyme

Oct. 31, 2024

“Sometimes you must bend the rules to get what you want.” In the case of using water in the purification of calpain-2, it was worth the risk.

Virtual issue celebrates water in ASBMB journals
Journal News

Virtual issue celebrates water in ASBMB journals

Oct. 30, 2024

Read a dozen gold open-access articles covering exciting research about the society’s 2024 Molecule of the year.

There are worse things in the water than E. coli
News

There are worse things in the water than E. coli

Oct. 29, 2024

E. coli levels determined whether Olympic swimmers could dive into the Seine this past summer. But are these bacteria the best proxy for water contamination?

Biobots arise from the cells of dead organisms
News

Biobots arise from the cells of dead organisms

Oct. 27, 2024

Given the right conditions, certain types of cells are able to self-assemble into new lifeforms after the organism they were once part of has died.